CRBP's Quality Score rose 2 points on Tue, Nov 10, to -8. It closed near its high of the day (2 chart checks started).
Follow CRBP's trial news. Pro members can get an alert when Corbus Pharmaceuticals Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 37% from Nov 5 to Nov 10.
“Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data.”
Down 66% over the year to Nov 9 while the S&P 500 rose 12%; up 37% since Nov 5.
2 reasons, from its filings, with the timeline, for Pro members.
| Holding it back | 58.6% more shares than a year ago |
| Latest filing | 8-K, Nov 10 |
ReportThis morning: the results are out. Past reports ›
In the newsCRBP: Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K...
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
Expected to report Mon Mar 8, before the open
2 more dates ahead: conferences, for Pro members.
About 5 quarters
Director Yong Ben sold 2,000 shares on Sep 14, under a planned sale. 13 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
CRBP is #266 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 266 |
Expected to report Mon Mar 8, before the open (in 118 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily attributable to a $15.0 million development milestone incurred in Q3 2026 pursuant to the CSPC licensing agreement for sutantatug envedotin.”
CRBP's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The Company had $115.3 million of cash, cash equivalents, and investments on hand as of September 30, 2026, which is expected to fund operations into 2028 based on current operating plans and planned expenditures.”
From its results filing (SEC filing · Nov 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | -3.7% | +11.7% | not yet |
| Aug 6, 2026 | -3.5% | +1.8% | +2.0% |
| May 12, 2026 | +1.9% | +3.5% | -9.9% |
RSI 40.0, MACD above signal, below both averages. Not scored.
One insider bought $126K across 3 filings, and one insider sold $1.7M across 1 filing, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CRBP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
“The biotechnology and pharmaceutical industries are characterized by a rapid pace of new innovation and discoveries, fierce competition and strong defense of intellectual property.”
CRBP scores -8 today, which Breakaway calls Poor. It is #266 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 37% from Nov 5 to Nov 10. Cash lasts about 5 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CRBP scores -8 today, which Breakaway calls Poor (below zero). That is #266 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CRBP's -8.
One insider bought $126K across 3 filings, and one insider sold $1.7M across 1 filing, in the last 6 months. The newest is Cormorant Asset Management, LP, Insider, who sold $1.7M on Oct 29. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.